Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
This study is currently recruiting participants.
Verified April 2013 by Prism Pharma Co., Ltd.
Sponsor:
Prism Pharma Co., Ltd.
Collaborator:
inVentiv Health Clinical
Information provided by (Responsible Party):
Prism Pharma Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01764477
First received: December 12, 2012
Last updated: April 17, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Laboratory studies suggest that the study drug may stop cancer cells from growing by affecting an interaction between proteins in the cells referred to as cAMP-response element-binding protein and ß-catenin.
The purpose of this research study is to determine the highest safe dose of study drug that may be used when it is given together with a chemotherapy drug to patients with cancer of the pancreas.
| Condition | Intervention | Phase |
|---|---|---|
|
Advanced Pancreatic Cancer Metastatic Pancreatic Cancer Pancreatic Adenocarcinoma |
Drug: PRI-724 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase Ib Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination With Continuous Intravenous Doses of PRI-724, a CBP/ β- Catenin Inhibitor, to Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy After Failing First-Line Therapy With FOLFIRINOX (or FOLFOX) |
Resource links provided by NLM:
Further study details as provided by Prism Pharma Co., Ltd.:
Primary Outcome Measures:
- The Maximum Tolerated Dose (MTD) of PRI-724 + Gemcitabine measured by the number of dose limiting toxicities (DLTs) that occur. [ Time Frame: 18 months. DLTs will be measured as they occur throughout the patients' time on study. ] [ Designated as safety issue: Yes ]If no DLT occurs in the first 3 patients of a cohort, the dose will be escalated to the next dose cohort. If 1 DLT occurs in the first 3 patients of a cohort, that cohort is expanded to 6 patients. If more than 1 DLT occurs in a 6 patient cohort, escalation is stopped & next lower dose is expanded to 12 patients to confirm the MTD.
Secondary Outcome Measures:
- Pharmacokinetic parameters of C max , T max , AUC (tau), and t ½. [ Time Frame: C 1 D 1 hrs 0, 1, 2, D 8 hrs 0, :15, :30, 1, 2, 4, 6, D 9 hrs 24, D 15 at hrs 0 ] [ Designated as safety issue: No ]The secondary outcome measures of PKs, PDs, MMP7, hair follicle sampling, and Response Criteria by RECIST comprise the correlative studies of this trial and are designed to evaluate PK profiles, assess and evaluate the utility of potential biomarkers, and evaluate antineoplastic activity of PRI-724 + Gemcitabine.
- Pharmacodynamic mRNA expression of survivin [ Time Frame: C 1 D 1, D 8, D 15, D 22, All Cycles D 22, end of treatment ] [ Designated as safety issue: No ]The secondary outcome measures of PKs, PDs, MMP7, hair follicle sampling, and Response Criteria by RECIST comprise the correlative studies of this trial and are designed to evaluate PK profiles, assess and evaluate the utility of potential biomarkers, and evaluate antineoplastic activity of PRI-724 + Gemcitabine
- Evaluation of antineoplastic activity of PRI-724 + gemcitabine per RECIST 1.1 criteria [ Time Frame: Screening, end of C 2, every 2 cycles, end of treatment ] [ Designated as safety issue: No ]The secondary outcome measures of PKs, PDs, MMP7, hair follicle sampling, and Response Criteria by RECIST comprise the correlative studies of this trial and are designed to evaluate PK profiles, assess and evaluate the utility of potential biomarkers, and evaluate antineoplastic activity of PRI-724 + Gemcitabine
- MMP7 levels in blood as ng/ml [ Time Frame: C 1 Wk 1, Wk 4, Wk 4 all cycles, end of treatment ] [ Designated as safety issue: No ]The secondary outcome measures of PKs, PDs, MMP7, hair follicle sampling, and Response Criteria by RECIST comprise the correlative studies of this trial and are designed to evaluate PK profiles, assess and evaluate the utility of potential biomarkers, and evaluate antineoplastic activity of PRI-724 + Gemcitabine.
- Gene expressions in hair follicle epithelial cells [ Time Frame: Screening, C 1 D 14, C 2 Wk 4, end of treatment ] [ Designated as safety issue: No ]The secondary outcome measures of PKs, PDs, MMP7, hair follicle sampling, and Response Criteria by RECIST comprise the correlative studies of this trial and are designed to evaluate PK profiles, assess and evaluate the utility of potential biomarkers, and evaluate antineoplastic activity of PRI-724 + Gemcitabine
| Estimated Enrollment: | 24 |
| Study Start Date: | March 2013 |
| Estimated Study Completion Date: | February 2015 |
| Estimated Primary Completion Date: | October 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: PRI-724 and Gemcitabine
This study will have one arm: all enrolled subjects will be treated with both PRI-724 and Gemcitabine.
|
Drug: PRI-724
Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle) PRI-724: Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle) |
Detailed Description:
PRI-724 is a small molecule antagonist that binds to the co-activator CBP thereby specifically inhibiting the subset of Wnt/β-catenin-driven genes that are up-regulated in cancer cells. PRI-724 is being developed as a potential antineoplastic agent.
Purpose:
To determine the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of sequential escalating doses per cohort of PRI-724 administered in combination with gemcitabine to patients with adenocarcinoma of the pancreas that is locally advanced, metastatic, or otherwise inoperable, who are candidates for second-line therapy after failing first-line therapy with FOLFIRINOX (i.e., folinic acid [leucovorin], fluorouracil, irinotecan, oxaliplatin)
- PRI-724: 320, 640, 905 mg/m2/day, continuous intravenous (CIV) infusion over 24 h, daily × 7 days, 1 week on with 1 week recovery × 2 (4 weeks equals 1 cycle)
- Gemcitabine: 1000 mg/m2 IV over 30 minutes; 3 weeks on with 1 week recovery (4 weeks equals 1 cycle)
Patients with documented, measurable or evaluable adenocarcinoma of the pancreas that is locally advanced, metastatic, or otherwise inoperable, who are candidates for second-line therapy after failing first-line therapy with FOLFIRINOX, will be entered into this phase 1b, multicenter, open-label, non-randomized, dose-escalation per cohort study. The trial is designed to evaluate the safety, tolerability, DLT(s), and MTD of escalating doses of PRI-724, a CBP/ β- catenin inhibitor, when administered in combination with a standard dose of gemcitabine. Correlative studies include characterization of the PK profiles of PRI-724 and gemcitabine, evaluation of the utility of potential PD markers of PRI-724 activity, as well as preliminary assessment of the antineoplastic activity of PRI-724 plus gemcitabine in this patient population.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female patients, > 18 years of age.
- Patients with a documented (histologically- or cytologically-proven) epithelial cell/adenocarcinoma of the pancreas that is relapsed, locally advanced, or metastatic.
- Patients with measurable or evaluable disease according to the response evaluation criteria in solid tumors
- Patients eligible for second-line therapy after failing first-line therapy with the regimen FOLFIRINOX.
- Patients with a malignancy that is currently not amenable to surgical intervention, due to either medical contraindications or non-resectability of the tumor.
- Patients with a Karnofsky Performance Status of 70% to 100% (or equivalent, Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1); Performance Status Evaluation), and an anticipated life expectancy of ≥ 3 months.
- Patients, both male and female, who are either not of childbearing potential or who agree to use a medically effective method of contraception during the study and for 3 months after the last dose of study drug.
- Patients with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.
Exclusion Criteria:
- Women who are pregnant or lactating. Women of child-bearing potential (WOCBP) and fertile men with a WOCBP partner, not using adequate birth control.
- Patients with islet cell tumors or other non-epithelial cell malignancies of the pancreas.
- Patients with known CNS (or leptomeningeal) metastases not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.
Patients with an active second malignancy within the last 2 years with the exception of:
- Treated, non-melanoma skin cancers
- Treated CIS of the breast or cervix
- Controlled, superficial bladder carcinoma
- T1a or b prostate carcinoma involving < 5% of resected tissue and PSA within normal limits (WNL) since resection
Patients with any of the following hematologic abnormalities at baseline:
- Hemoglobin < 9.0 g/dL
- Absolute neutrophil count (ANC) < 1,500 per mm3
- Platelet count < 100,000 per mm3
Patients with any of the following serum chemistry abnormalities at baseline:
- Total bilirubin > 1.5× the ULN for the institution, unless considered due to Gilbert's Syndrome
- AST or ALT > 3× the ULN for the institution (> 5× ULN if due to hepatic involvement by tumor)
- Serum albumin < 2.5 g/dL
- Serum creatinine > 1.5× ULN (or a calculated creatinine clearance < 60 mL/min/1.73 m2)
Patients with a significant cardiovascular disease or condition, including:
- Congestive heart failure (CHF) currently requiring therapy
- Need for anti-arrhythmic therapy for a ventricular arrhythmias
- Severe conduction disturbances
- Angina pectoris requiring therapy
- Left ventricular ejection fraction (LVEF) < 50% by MUGA or echocardiogram
- QTcF interval > 450 msec (males) or > 470 msec (females)
- Uncontrolled hypertension (per Investigator's discretion)
- Class III or IV cardiovascular disease according to the New York Heart Association's (NYHA) Functional Criteria.
- Myocardial infarction (MI) within 6 months prior to first study drug administration
- Patients with known osteopenia or osteoporosis.
- Patients with a known or suspected hypersensitivity to either gemcitabine or any of the components of PRI-724.
- Patients with a history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
- Patients with any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks prior to first study drug administration.
- Patients with inadequate recovery from acute toxicity associated with any prior antineoplastic therapy
- Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 1 month prior to first study drug administration.
- Patients with any other life-threatening illness, significant organ system dysfunction, or clinically significant laboratory abnormality, which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the study drug
- Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies
- Patients with the inability, in the opinion of the Investigator, to comply with the protocol requirements
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01764477
Contacts
| Contact: Andria E. Cress, BA | 847-444-3411 | andria.cress@inventivhealth.com |
| Contact: Craig Schleyer | 847-444-3398 | craig.schleyer@inventivhealth.com |
Locations
| United States, Arizona | |
| Mayo Clinic Arizona | Recruiting |
| Scottsdale, Arizona, United States, 85259 | |
| Contact: Donald W Northfelt, M.D. 507-538-7623 | |
| Principal Investigator: Donald W. Northfelt, M.D. | |
| United States, California | |
| USC Norris Comprehensive Cancer Center | Not yet recruiting |
| Los Angeles, California, United States, 90033 | |
| Contact: Heinz-Josef Lenz, M.D. 507-538-7623 | |
| Principal Investigator: Heinz-Josef Lenz, M.D. | |
| United States, Florida | |
| Mayo Clinic Jacksonville, FL | Not yet recruiting |
| Jacksonville, Florida, United States, 32224 | |
| Contact: George P Kim, M.D. 507-538-7623 | |
| Principal Investigator: George P. Kim, M.D. | |
| United States, Minnesota | |
| Mayo Clinic | Recruiting |
| Rochester, Minnesota, United States, 55905 | |
| Contact: Robert R McWilliams, M.D. 507-538-7623 | |
| Principal Investigator: Robert R. McWilliams, M.D. | |
Sponsors and Collaborators
Prism Pharma Co., Ltd.
inVentiv Health Clinical
Investigators
| Principal Investigator: | Robert R. McWilliams, M.D. | Mayo Clinic |
More Information
No publications provided
| Responsible Party: | Prism Pharma Co., Ltd. |
| ClinicalTrials.gov Identifier: | NCT01764477 History of Changes |
| Other Study ID Numbers: | PRI-724-102 |
| Study First Received: | December 12, 2012 |
| Last Updated: | April 17, 2013 |
| Health Authority: | United States: Institutional Review Board United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Adenocarcinoma Adenocarcinoma, Mucinous Pancreatic Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Cystic, Mucinous, and Serous Digestive System Neoplasms Neoplasms by Site Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases |
Gemcitabine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents Therapeutic Uses Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Radiation-Sensitizing Agents |
ClinicalTrials.gov processed this record on May 22, 2013